NOVARTIS logo.jpg
Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing
March 24, 2020 02:15 ET | Novartis International AG
Interim SPR1NT data showed presymptomatic babies with SMA treated with Zolgensma® (onasemnogene abeparvovec-xioi) soon after birth achieved age-appropriate motor milestones In addition to meeting both...
NOVARTIS logo.jpg
AveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2
March 24, 2020 02:13 ET | Novartis International AG
SMA Type 2 patients between two and five years of age who received Dose B met the primary efficacy endpoint with a remarkable mean increase of 6.0 points in HFMSE scores from baseline to month 12,...
NOVARTIS logo.jpg
Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response
March 20, 2020 12:00 ET | Novartis International AG
Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Novartis Sandoz division will pursue appropriate regulatory...
NOVARTIS logo.jpg
Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA)
March 19, 2020 02:15 ET | Novartis International AG
Zolgensma® (onasemnogene abeparvovec), a one-time administered gene therapy, is approved for the treatment of SMA in patients under the age of two, including those who are pre-symptomatic at...
NOVARTIS logo.jpg
Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy
March 18, 2020 17:01 ET | Novartis International AG
Inclisiran, an investigational medicine, showed durable and potent reduction of low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk...
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration à l’Assemblée générale annuelle
February 28, 2020 07:00 ET | Novartis International AG
Les actionnaires approuvent la 23e augmentation consécutive du dividende qui passe à CHF 2.95 (+4%) par action pour l’année 2019, soit un rendement de 3,5%1 et une distribution du free cash-flow...
Die Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrates gut
February 28, 2020 07:00 ET | Novartis International AG
Die Aktionäre bewilligen die 23. Dividendenerhöhung in Folge. Für 2019 wird die Dividende auf CHF 2.95 (+4%) je Aktie erhöht, was einer Rendite von 3.5%1 und einem Anteil von etwa 54% des freien...
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
February 28, 2020 07:00 ET | Novartis International AG
Shareholders approve 23rd consecutive dividend increase to CHF 2.95 (+4%) per share for 2019; representing a 3.5%1 yield and approximately 54% payout of free cash flow Shareholders confirm Dr. Joerg...
NOVARTIS logo.jpg
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
February 11, 2020 01:15 ET | Novartis International AG
FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping (METex14) mutated advanced non-small cell lung cancer...
Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicines
January 31, 2020 01:30 ET | Novartis International AG
Successful acquisition of Aspen’s Japanese operations and assets reinforces strategic focus on Japan, world’s third largest market for generics and off-patent medicinesAcquired portfolio complements...